AbCellera Biologics (ABCL) Net Income towards Common Stockholders: 2020-2023
Historic Net Income towards Common Stockholders for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$47.1 million.
- AbCellera Biologics' Net Income towards Common Stockholders fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- Latest data reveals that AbCellera Biologics reported Net Income towards Common Stockholders of -$47.1 million as of Q4 2023, which was down 64.80% from -$28.6 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Net Income towards Common Stockholders registered a high of $168.6 million during Q1 2022, and its lowest value of -$47.1 million during Q4 2023.
- For the 3-year period, AbCellera Biologics' Net Income towards Common Stockholders averaged around $13.8 million, with its median value being -$14.1 million (2021).
- The largest annual percentage gain for AbCellera Biologics' Net Income towards Common Stockholders in the last 5 years was 5,700.62% (2021), contrasted with its biggest fall of 693.91% (2021).
- Over the past 4 years, AbCellera Biologics' Net Income towards Common Stockholders (Quarterly) stood at $117.0 million in 2020, then crashed by 48.76% to $59.9 million in 2021, then slumped by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.1 million in 2023.
- Its last three reported values are -$47.1 million in Q4 2023, -$28.6 million for Q3 2023, and -$30.5 million during Q2 2023.